Woburn, MA, Aug. 3, 2016 – CellMosaic announced today that the United States Patent and Trademark Office (USPTO) issued a formal Notice of Allowance for another patent on AqueaTether (AqT™) molecules (Application No. 14/156,224 entitled “Novel crosslinking reagents, macromolecules, therapeutic bioconjugates, and synthetic methods thereof”). Upon issuance, the patent will provide intellectual property protection for a broad range of AqT™ molecules constructed from sugar alcohols or modified sugar alcohols. AqT™ molecules are able to improve performance across a range of life science applications: preparing bioconjugation-based research reagents with enhanced water solubility and activity, diagnostic reagents for signal amplification, target-specific drug delivery such as antibody-drug conjugates (ADCs), and for delivering therapeutic biopolymers conjugated with small molecules.
“CellMosaic pioneered the concept of using sugar alcohol molecules to assemble novel architectures for bioconjugation-based drug development and drug delivery. This patent, along with previously issued patents for the AqT™ platform, establishes CellMosaic as the leader in drug delivery based on sugar alcohols. These patents allow the construction of any AqT™ architectures derived from sugar alcohols for use in drug development and research applications without IP interference,” said Dr. Yumei Huang, founder and CEO of CellMosaic. “We are pleased that the USPTO recognizes our innovation. To fulfill our commitment in drug discovery and development, CellMosaic has built a separate business unit, called AqT™ therapeutics, to work with our partners utilizing our AqT™ platform to cost- and time-effectively improve conjugated drug performance, thereby helping create significant value for their programs.”
About AqT™ molecules
AqT™ molecules are novel chemical entities designed and created at CellMosaic based on sugar alcohol monomers. Sugar alcohols occur naturally in foods and are often used as ingredients in sweeteners. AqT™ molecules are super-hydrophilic molecules and have many advantages over classical linkers and polymers, such as PEG and PLGA, in terms of improved hydrophilicity, biodegradability, loading, versatility, and ease of customization. AqT™molecules allow maximum flexibility in building and generating novel drug conjugates with enhanced therapeutic profiles due to their super-hydrophilic, mono-disperse, and multifunctional natures. For example, shorter AqT™cross linkers allow convenient linking of hydrophobic drug molecules to a targeting biopolymer in water without a loss of activity, improving efficacy in vivo. When used to label a therapeutic biopolymer, an AqT™ polymer can increase the protein’s stability in circulation, reducing its immunogenicity and decreasing the frequency of dosing. The mono-dispersed AqT™ polymer makes homogeneous conjugation possible, a manufacturing process that is predictable and easy to control. The AqT™ polymer can also be designed with multiple conjugation sites for loading hydrophobic chemotherapeutic agents. This will greatly increase the solubility and stability of hydrophobic drugs, increasing the amount of targeted drug delivery to the tumors and potentially reducing undesirable side effects and the therapeutic dosing frequency.
About CellMosaic, Inc.
CellMosaic, Inc. is an innovator and leader in bioconjugation and crosslinking technologies. Several key technologies are being developed at CellMosaic, including oxLink™ technologies for studying protein–protein interactions; NeIon™ technologies for detecting and quantitating trace amounts of analytes of interest; super-hydrophilic AqueaTether™ linkers for clean conjugation of antibody/protein/peptide/oligo with small molecule drugs; biocompatible, biodegradable, mono-dispersed AqueaTether™ macromolecules for modification of protein/peptide/oligo drugs and the preparation of highly loaded small molecule drugs for better delivery; and bioconjugation platform technologies involving screening, labeling/crosslinking, purification, and analysis of any bioconjugate. The company is also actively engaged in serving life science communities by providing custom synthesis of high quality bioconjugate products.
About AqueaTether™ Therapeutics
AqueaTether™Therapeutics is a division of CellMosaic created in 2016. AqueaTether™ Therapeutics focuses on the discovery and development of novel hybrid drug entities beyond the conventional drug classes by using AqT™ conjugation and delivery platform technologies. We works together with our partners to advance their programs. For more information regarding AqT™-based bioconjugate drugs, please visit our website: www.aqttherapeutics.com.